©The Author(s) 2021.
World J Gastroenterol. Jul 21, 2021; 27(27): 4453-4467
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4453
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4453
Table 1 Baseline characteristics and plasma levels of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor
| Characteristic | HCC patients (n = 240) |
| Age, mean age ± SD, year | 60.9 ± 11.2 |
| Male sex, n (%) | 193 (80.4) |
| BMI, mean ± SD, kg/m2 | 24.1 ± 3.0 |
| Etiology, n (%) | |
| HBV/HCV/HBV + HCV | 167 (69.6)/24 (10)/2 (0.8) |
| Alcohol/Others | 28 (11.7)/19 (7.9) |
| Presence of cirrhosis, n (%) | 184 (76.7) |
| Child-Pugh score, n (%) | |
| A/B/C | 204 (85.1)/35 (14.5)/1 (0.4) |
| ECOG performance status, n (%) | |
| 0/1–2/3 | 156 (65)/80 (33.3)/4 (1.7) |
| Maximal tumor size, median (IQR), cm | 3.6 (2.0–7.0) |
| Multi-nodularity of tumor, n (%) | 105 (43.8) |
| Vascular invasion of HCC, n (%) | 45 (18.8) |
| Presence of distant metastasis, n (%) | 18 (7.5) |
| BCLC staging, n (%) | |
| 0/A | 52 (21.7)/81 (33.8) |
| B/C/D | 43 (17.9)/59 (24.6)/5 (2.1) |
| TNM staging, n (%) | |
| I/II | 115 (48.0)/42 (17.5) |
| III/IV | 65 (27.1)/18 (7.5) |
| Initial treatment, n (%) | |
| Resection | 34 (14.2) |
| RFA/TACE | 27 (11.3)/165 (69.2) |
| Sorafenib/BSC | 2 (0.8)/11 (4.6) |
| Laboratory results | |
| WBC, median (IQR), × 103/uL | 5.1 (4.0–6.6) |
| Hemoglobin, median (IQR), g/dL | 13.6 (12.0–14.8) |
| Platelet count, median (IQR), × 109/uL | 130 (88–184) |
| Prothrombin time, median (IQR), INR | 1.11 (1.04–1.18) |
| AST, median (IQR), IU/mL | 45 (32–73) |
| ALT, median (IQR), IU/mL | 38 (23–61) |
| Albumin; median (IQR), g/dL | 4.0 (3.5–4.2) |
| Total bilirubin, median (IQR), mg/dL | 0.8 (0.5–1.1) |
| Creatinine, median (IQR), mg/dL | 0.8 (0.7–1.0) |
| AFP, median (IQR), ng/mL | 17.9 (4.0–698) |
| Angiogenesis marker | |
| Ang-1, median (IQR), pg/mL | 3216 (1565–6266) |
| Ang-2, median (IQR), pg/mL | 1684 (1107–3064) |
| Ang-2/Ang-1 ratio, median (IQR) | 0.56 (0.25–1.39) |
| VEGF, median (IQR), pg/mL | 26.5 (13.8–51.3) |
| NLR, mean ± SD | 2.8 ± 3.5 |
| PLR, mean ± SD | 118.2 ± 119.7 |
- Citation: Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol 2021; 27(27): 4453-4467
- URL: https://www.wjgnet.com/1007-9327/full/v27/i27/4453.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i27.4453